{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:48:16Z","timestamp":1782366496609,"version":"3.54.5"},"reference-count":255,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"DOI":"10.1038\/s41418-026-01792-9","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:06:56Z","timestamp":1782360416000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The emerging roles of alternative splicing in modulating tumor immune responses and immunotherapies"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7656-2590","authenticated-orcid":false,"given":"Xinyu","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengyun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6129-643X","authenticated-orcid":false,"given":"Yanan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4174-4028","authenticated-orcid":false,"given":"Zigang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-5625","authenticated-orcid":false,"given":"Kangdong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"1792_CR1","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41576-022-00514-4","volume":"23","author":"CJ Wright","year":"2022","unstructured":"Wright CJ, Smith CWJ, Jiggins CD. Alternative splicing as a source of phenotypic diversity. Nat Rev Genet. 2022;23:697\u2013710.","journal-title":"Nat Rev Genet"},{"key":"1792_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","volume":"23","author":"RK Bradley","year":"2023","unstructured":"Bradley RK, Anczuk\u00f3w O. RNA splicing dysregulation and the hallmarks of cancer. Nat Rev Cancer. 2023;23:135\u201355.","journal-title":"Nat Rev Cancer"},{"key":"1792_CR3","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/nar\/gkad067","volume":"51","author":"M Egli","year":"2023","unstructured":"Egli M, Manoharan M. Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res. 2023;51:2529\u201373.","journal-title":"Nucleic Acids Res"},{"key":"1792_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110718","volume":"123","author":"X Song","year":"2023","unstructured":"Song X, Li X, Ge Y, Song J, Wei Q, He M, et al. Alternative splicing events and function in the tumor microenvironment: new opportunities and challenges. Int Immunopharmacol. 2023;123:110718.","journal-title":"Int Immunopharmacol"},{"key":"1792_CR5","doi-asserted-by":"crossref","unstructured":"Zheng S, Gillespie E, Naqvi AS, Hayer KE, Ang Z, Torres-Diz M, et al. Modulation of CD22 protein expression in childhood leukemia by pervasive splicing aberrations: implications for CD22-directed immunotherapies. Blood Cancer Discov. 2022;3:103\u201315.","DOI":"10.1158\/2643-3230.BCD-21-0087"},{"key":"1792_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02411-1","volume":"22","author":"L Schulz","year":"2021","unstructured":"Schulz L, Torres-Diz M, Cort\u00e9s-L\u00f3pez M, Hayer KE, Asnani M, Tasian SK, et al. Direct long-read RNA sequencing identifies a subset of questionable exitrons likely arising from reverse transcription artifacts. Genome Biol. 2021;22:190.","journal-title":"Genome Biol"},{"key":"1792_CR7","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1101\/gad.338962.120","volume":"34","author":"S Cherry","year":"2020","unstructured":"Cherry S, Lynch KW. Alternative splicing and cancer: insights, opportunities, and challenges from an expanding view of the transcriptome. Genes Dev. 2020;34:1005\u201316.","journal-title":"Genes Dev"},{"key":"1792_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13046-021-01874-1","volume":"40","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Wang D, Peng M, Tang L, Ouyang J, Xiong F, et al. Single-cell RNA sequencing in cancer research. J Exp Clin Cancer Res. 2021;40:81.","journal-title":"J Exp Clin Cancer Res"},{"key":"1792_CR9","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/s41587-021-01108-x","volume":"39","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhao Y, Bollas A, Wang Y, Au KF. Nanopore sequencing technology, bioinformatics and applications. Nat Biotechnol. 2021;39:1348\u201365.","journal-title":"Nat Biotechnol"},{"key":"1792_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1146\/annurev-biochem-060614-034316","volume":"84","author":"Y Lee","year":"2015","unstructured":"Lee Y, Rio DC. Mechanisms and regulation of alternative pre-mRNA splicing. Annu Rev Biochem. 2015;84:291\u2013323.","journal-title":"Annu Rev Biochem"},{"key":"1792_CR11","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S0960-9822(02)00599-7","volume":"6","author":"JP Kreivi","year":"1996","unstructured":"Kreivi JP, Lamond AI. RNA splicing: unexpected spliceosome diversity. Curr Biol. 1996;6:802\u20135.","journal-title":"Curr Biol"},{"key":"1792_CR12","doi-asserted-by":"crossref","unstructured":"El Marabti E, Malek J, Younis I. Minor intron splicing from basic science to disease. Int J Mol Sci. 2021;22:6062.","DOI":"10.3390\/ijms22116062"},{"key":"1792_CR13","first-page":"7066","volume":"48","author":"DC Moyer","year":"2020","unstructured":"Moyer DC, Larue GE, Hershberger CE, Roy SW, Padgett RA. Comprehensive database and evolutionary dynamics of U12-type introns. Nucleic Acids Res. 2020;48:7066\u201378.","journal-title":"Nucleic Acids Res"},{"key":"1792_CR14","doi-asserted-by":"crossref","unstructured":"Will CL, L\u00fchrmann R. Spliceosome structure and function. Cold Spring Harb Perspect Biol. 2011;3:a003707.","DOI":"10.1101\/cshperspect.a003707"},{"key":"1792_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41586-018-0323-8","volume":"559","author":"C Plaschka","year":"2018","unstructured":"Plaschka C, Lin P-C, Charenton C, Nagai K. Prespliceosome structure provides insights into spliceosome assembly and regulation. Nature. 2018;559:419\u201322.","journal-title":"Nature"},{"key":"1792_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14548","volume":"523","author":"THD Nguyen","year":"2015","unstructured":"Nguyen THD, Galej WP, Bai X, Savva CG, Newman AJ, Scheres SHW, et al. The architecture of the spliceosomal U4\/U6.U5 tri-snRNP. Nature. 2015;523:47\u201352.","journal-title":"Nature"},{"key":"1792_CR17","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cell.2018.01.010","volume":"172","author":"D Haselbach","year":"2018","unstructured":"Haselbach D, Komarov I, Agafonov DE, Hartmuth K, Graf B, Dybkov O, et al. Structure and conformational dynamics of the human spliceosomal B(act) complex. Cell. 2018;172:454\u201364.e11.","journal-title":"Cell"},{"key":"1792_CR18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/s41586-022-05204-z","volume":"609","author":"M Hluch\u00fd","year":"2022","unstructured":"Hluch\u00fd M, Gajdu\u0161kov\u00e1 P, Ruiz de Los Mozos I, R\u00e1jeck\u00fd M, Kluge M, Berger B-T, et al. CDK11 regulates pre-mRNA splicing by phosphorylation of SF3B1. Nature. 2022;609:829\u201334.","journal-title":"Nature"},{"key":"1792_CR19","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.cell.2017.04.033","volume":"169","author":"X Zhang","year":"2017","unstructured":"Zhang X, Yan C, Hang J, Finci LI, Lei J, Shi Y. An atomic structure of the human spliceosome. Cell. 2017;169:918\u201329.e14.","journal-title":"Cell"},{"key":"1792_CR20","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.molcel.2011.12.034","volume":"45","author":"A Hegele","year":"2012","unstructured":"Hegele A, Kamburov A, Grossmann A, Sourlis C, Wowro S, Weimann M, et al. Dynamic protein-protein interaction wiring of the human spliceosome. Mol Cell. 2012;45:567\u201380.","journal-title":"Mol Cell"},{"key":"1792_CR21","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1126\/science.aar3462","volume":"358","author":"S Liu","year":"2017","unstructured":"Liu S, Li X, Zhang L, Jiang J, Hill RC, Cui Y, et al. Structure of the yeast spliceosomal postcatalytic P complex. Science. 2017;358:1278\u201383.","journal-title":"Science"},{"key":"1792_CR22","doi-asserted-by":"crossref","unstructured":"Gerstberger S, Hafner M, Tuschl T. A census of human RNA-binding proteins. Nat Rev Genet. 2014;15:829\u201345.","DOI":"10.1038\/nrg3813"},{"key":"1792_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1146\/annurev-biochem-091719-064225","volume":"89","author":"ME Wilkinson","year":"2020","unstructured":"Wilkinson ME, Charenton C, Nagai K. RNA splicing by the spliceosome. Annu Rev Biochem. 2020;89:359\u201388.","journal-title":"Annu Rev Biochem"},{"key":"1792_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrm3742","volume":"15","author":"AG Matera","year":"2014","unstructured":"Matera AG, Wang Z. A day in the life of the spliceosome. Nat Rev Mol Cell Biol. 2014;15:108\u201321.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1792_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.semcdb.2017.10.011","volume":"79","author":"M Krausov\u00e1","year":"2018","unstructured":"Krausov\u00e1 M, Stan\u011bk D. snRNP proteins in health and disease. Semin Cell Dev Biol. 2018;79:92\u2013102.","journal-title":"Semin Cell Dev Biol"},{"key":"1792_CR26","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1093\/nar\/gkad161","volume":"51","author":"A Mironov","year":"2023","unstructured":"Mironov A, Petrova M, Margasyuk S, Vlasenok M, Mironov AA, Skvortsov D, et al. Tissue-specific regulation of gene expression via unproductive splicing. Nucleic Acids Res. 2023;51:3055\u201366.","journal-title":"Nucleic Acids Res"},{"key":"1792_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41586-023-06913-9","volume":"626","author":"S Wang","year":"2024","unstructured":"Wang S, DeLeon C, Sun W, Quake SR, Roth BL, S\u00fcdhof TC. Alternative splicing of latrophilin-3 controls synapse formation. Nature. 2024;626:128\u201335.","journal-title":"Nature"},{"key":"1792_CR28","doi-asserted-by":"publisher","first-page":"e0187357","DOI":"10.1371\/journal.pone.0187357","volume":"12","author":"PC Spinosa","year":"2017","unstructured":"Spinosa PC, Luker KE, Luker GD, Linderman JJ. The CXCL12\/CXCR7 signaling axis, isoforms, circadian rhythms, and tumor cellular composition dictate gradients in tissue. PLoS One. 2017;12:e0187357.","journal-title":"PLoS One"},{"key":"1792_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1084\/jem.191.1.157","volume":"191","author":"H Nishimura","year":"2000","unstructured":"Nishimura H, Yajima T, Naiki Y, Tsunobuchi H, Umemura M, Itano K, et al. Differential roles of Interleukin 15 mRNA isoforms generated by alternative splicing in immune responses in vivo. J Exp Med. 2000;191:157\u201370.","journal-title":"J Exp Med"},{"key":"1792_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20:131.","journal-title":"Mol Cancer"},{"key":"1792_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-022-01528-6","volume":"21","author":"PR Pandey","year":"2022","unstructured":"Pandey PR, Young KH, Kumar D, Jain N. RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics. Mol Cancer. 2022;21:58.","journal-title":"Mol Cancer"},{"key":"1792_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107713","volume":"215","author":"C Yong","year":"2025","unstructured":"Yong C, Liang Y, Wang M, Jin W, Fan X, Wang Z, et al. Alternative splicing: A key regulator in T cell response and cancer immunotherapy. Pharm Res. 2025;215:107713.","journal-title":"Pharm Res"},{"key":"1792_CR33","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-024-08552-0","volume":"639","author":"DW Kwok","year":"2025","unstructured":"Kwok DW, Stevers NO, Etxeberria I, Nejo T, Colton Cove M, Chen LH, et al. Tumour-wide RNA splicing aberrations generate actionable public neoantigens. Nat. 2025;639:463\u201373.","journal-title":"Nat"},{"key":"1792_CR34","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1007\/s00262-023-03534-z","volume":"72","author":"M Wahid","year":"2023","unstructured":"Wahid M, Pratoomthai B, Egbuniwe IU, Evans HR, Babaei-Jadidi R, Amartey JO, et al. Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T ce. Cancer Immunol Immunother. 2023;72:4001\u201314.","journal-title":"Cancer Immunol Immunother"},{"key":"1792_CR35","doi-asserted-by":"crossref","unstructured":"Silva AL, Faria M, Matos P. Inflammatory microenvironment modulation of alternative splicing in cancer: a way to adapt BT - tumor microenvironment : the main driver of metabolic adaptation. In: Serpa J, editor. Cham: Springer International Publishing. 2020;1219:243\u201358.","DOI":"10.1007\/978-3-030-34025-4_13"},{"key":"1792_CR36","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1261\/rna.457207","volume":"13","author":"JY Ip","year":"2007","unstructured":"Ip JY, Tong A, Pan Q, Topp JD, Blencowe BJ, Lynch KW. Global analysis of alternative splicing during T-cell activation. RNA. 2007;13:563\u201372.","journal-title":"RNA"},{"key":"1792_CR37","doi-asserted-by":"publisher","first-page":"e40032","DOI":"10.1371\/journal.pone.0040032","volume":"7","author":"MJ Butte","year":"2012","unstructured":"Butte MJ, Lee SJ, Jesneck J, Keir ME, Haining WN, Sharpe AH. CD28 costimulation regulates genome-wide effects on alternative splicing. PLoS One. 2012;7:e40032.","journal-title":"PLoS One"},{"key":"1792_CR38","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/eji.1830190403","volume":"19","author":"LM Pilarski","year":"1989","unstructured":"Pilarski LM, Gillitzer R, Zola H, Shortman K, Scollay R. Definition of the thymic generative lineage by selective expression of high molecular weight isoforms of CD45 (T200). Eur J Immunol. 1989;19:589\u201397.","journal-title":"Eur J Immunol"},{"key":"1792_CR39","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/j.1460-2075.1994.tb06322.x","volume":"13","author":"D Chui","year":"1994","unstructured":"Chui D, Ong CJ, Johnson P, Teh HS, Marth JD. Specific CD45 isoforms differentially regulate T cell receptor signaling. EMBO J. 1994;13:798\u2013807.","journal-title":"EMBO J"},{"key":"1792_CR40","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.90088","volume":"2","author":"E Picarda","year":"2017","unstructured":"Picarda E, B\u00e9zie S, Boucault L, Autrusseau E, Kilens S, Meistermann D, et al. Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells. JCI insight. 2017;2:e90088.","journal-title":"JCI insight"},{"key":"1792_CR41","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0198-8859(02)00379-8","volume":"63","author":"K Fukuhara","year":"2002","unstructured":"Fukuhara K, Okumura M, Shiono H, Inoue M, Kadota Y, Miyoshi S, et al. A study on CD45 isoform expression during T-cell development and selection events in the human thymus. Hum Immunol. 2002;63:394\u2013404.","journal-title":"Hum Immunol"},{"key":"1792_CR42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1146\/annurev.immunol.21.120601.140946","volume":"21","author":"ML Hermiston","year":"2003","unstructured":"Hermiston ML, Xu Z, Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol. 2003;21:107\u201337.","journal-title":"Annu Rev Immunol"},{"key":"1792_CR43","doi-asserted-by":"crossref","unstructured":"Courtney AH, Shvets AA, Lu W, Griffante G, Mollenauer M, Horkova V, et al. CD45 functions as a signaling gatekeeper in T cells. Sci Signal. 2019;12:eaaw8151.","DOI":"10.1126\/scisignal.aaw8151"},{"key":"1792_CR44","first-page":"3","volume":"4","author":"H Xu","year":"2017","unstructured":"Xu H, Turnquist HR, Hoffman R, Billiar TR. Role of the IL-33-ST2 axis in sepsis. Mil Med Res. 2017;4:3.","journal-title":"Mil Med Res"},{"key":"1792_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2017.12.014","volume":"343","author":"M Akimoto","year":"2019","unstructured":"Akimoto M, Takenaga K. Role of the IL-33\/ST2L axis in colorectal cancer progression. Cell Immunol. 2019;343:103740.","journal-title":"Cell Immunol"},{"key":"1792_CR46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2218033120","volume":"120","author":"M Akimoto","year":"2023","unstructured":"Akimoto M, Susa T, Okudaira N, Koshikawa N, Hisaki H, Iizuka M, et al. Hypoxia induces downregulation of the tumor-suppressive sST2 in colorectal cancer cells via the HIF-nuclear IL-33-GATA3 pathway. Proc Natl Acad Sci USA. 2023;120:e2218033120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1792_CR47","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1093\/emboj\/20.15.4194","volume":"20","author":"S Weg-Remers","year":"2001","unstructured":"Weg-Remers S, Ponta H, Herrlich P, K\u00f6nig H. Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J. 2001;20:4194\u2013203.","journal-title":"EMBO J"},{"key":"1792_CR48","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-018-0605-5","volume":"11","author":"C Chen","year":"2018","unstructured":"Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;11:64.","journal-title":"J Hematol Oncol"},{"key":"1792_CR49","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nature01153","volume":"420","author":"N Matter","year":"2002","unstructured":"Matter N, Herrlich P, K\u00f6nig H. Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature. 2002;420:691\u20135.","journal-title":"Nature"},{"key":"1792_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1380821","volume":"14","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Wang X, Liu Y, Xu H, Ye C. Pan-cancer and single-cell analyses identify CD44 as an immunotherapy response predictor and regulating macrophage polarization and tumor progression in colorectal cancer. Front Oncol. 2024;14:1380821.","journal-title":"Front Oncol"},{"key":"1792_CR51","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1261\/rna.079137.122","volume":"28","author":"G Galarza-Mu\u00f1oz","year":"2022","unstructured":"Galarza-Mu\u00f1oz G, Kennedy-Boone D, Schott G, Bradrick SS, Garcia-Blanco MA. Antisense modulation of IL7R splicing to control sIL7R expression in human CD4(+) T cells. RNA. 2022;28:1058\u201373.","journal-title":"RNA"},{"key":"1792_CR52","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1158\/2326-6066.CIR-19-0679","volume":"9","author":"A Bernard","year":"2021","unstructured":"Bernard A, Hibos C, Richard C, Viltard E, Chevrier S, Lemoine S, et al. The tumor microenvironment impairs Th1 IFN\u03b3 secretion through alternative splicing modifications of Irf1 pre-mRNA. Cancer Immunol Res. 2021;9:324\u201336.","journal-title":"Cancer Immunol Res"},{"key":"1792_CR53","doi-asserted-by":"publisher","first-page":"e6104","DOI":"10.1371\/journal.pone.0006104","volume":"4","author":"RKW Mailer","year":"2009","unstructured":"Mailer RKW, Falk K, R\u00f6tzschke O. Absence of leucine zipper in the natural FOXP3Delta2Delta7 isoform does not affect dimerization but abrogates suppressive capacity. PLoS One. 2009;4:e6104.","journal-title":"PLoS One"},{"key":"1792_CR54","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/pd.2613","volume":"30","author":"R Harbuz","year":"2010","unstructured":"Harbuz R, Lespinasse J, Boulet S, Francannet C, Creveaux I, Benkhelifa M, et al. Identification of new FOXP3 mutations and prenatal diagnosis of IPEX syndrome. Prenat Diagn. 2010;30:1072\u20138.","journal-title":"Prenat Diagn"},{"key":"1792_CR55","doi-asserted-by":"crossref","unstructured":"Blake D, Radens CM, Ferretti MB, Gazzara MR, Lynch KW. Alternative splicing of apoptosis genes promotes human T cell survival. Elife. 2022;11:e80953.","DOI":"10.7554\/eLife.80953"},{"key":"1792_CR56","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1182\/blood.V99.6.2138","volume":"99","author":"H Hanawa","year":"2002","unstructured":"Hanawa H, Ma Y, Mikolajczak SA, Charles ML, Yoshida T, Yoshida R, et al. A novel costimulatory signaling in human T lymphocytes by a splice variant of CD28. Blood. 2002;99:2138\u201345.","journal-title":"Blood"},{"key":"1792_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-022-00419-7","volume":"16","author":"Y Hitomi","year":"2022","unstructured":"Hitomi Y, Aiba Y, Ueno K, Nishida N, Kawai Y, Kawashima M, et al. rs2013278 in the multiple immunological-trait susceptibility locus CD28 regulates the production of non-functional splicing isoforms. Hum Genomics. 2022;16:46.","journal-title":"Hum Genomics"},{"key":"1792_CR58","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-22-0702","volume":"11","author":"X Li","year":"2023","unstructured":"Li X, Li J, Zheng Y, Lee SJ, Zhou J, Giobbie-Hurder A, et al. Granulocyte-macrophage colony-stimulating factor influence on soluble and membrane-bound ICOS in combination with immune checkpoint blockade. Cancer Immunol Res. 2023;11:1100\u201313.","journal-title":"Cancer Immunol Res"},{"key":"1792_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11292","volume":"7","author":"I Meininger","year":"2016","unstructured":"Meininger I, Griesbach RA, Hu D, Gehring T, Seeholzer T, Bertossi A, et al. Alternative splicing of MALT1 controls signalling and activation of CD4(+) T cells. Nat Commun. 2016;7:11292.","journal-title":"Nat Commun"},{"key":"1792_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abh2095","volume":"6","author":"TJ O\u2019Neill","year":"2021","unstructured":"O\u2019Neill TJ, Seeholzer T, Gewies A, Gehring T, Giesert F, Hamp I, et al. TRAF6 prevents fatal inflammation by homeostatic suppression of MALT1 protease. Sci Immunol. 2021;6:eabh2095.","journal-title":"Sci Immunol"},{"key":"1792_CR61","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2018.12.010","volume":"176","author":"P Baeza-Centurion","year":"2019","unstructured":"Baeza-Centurion P, Mi\u00f1ana B, Schmiedel JM, Valc\u00e1rcel J, Lehner B. Combinatorial genetics reveals a scaling law for the effects of mutations on splicing. Cell. 2019;176:549\u2013563.e23.","journal-title":"Cell"},{"key":"1792_CR62","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bjh.18773","volume":"203","author":"A Roeser","year":"2023","unstructured":"Roeser A, Lazarus AH, Mah\u00e9vas M. B cells and antibodies in refractory immune thrombocytopenia. Br J Haematol. 2023;203:43\u201353.","journal-title":"Br J Haematol"},{"key":"1792_CR63","doi-asserted-by":"crossref","unstructured":"Jing J, Zhu D, Wang X, An J, Liu Z, Zhang Q. The link between aberrant splicing and B cell infiltration in breast cancer hormone therapy. Endocr Relat Cancer. 2022;29(5):251\u201366.","DOI":"10.1530\/ERC-21-0199"},{"key":"1792_CR64","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1101\/gr.116335.110","volume":"21","author":"JM Toung","year":"2011","unstructured":"Toung JM, Morley M, Li M, Cheung VG. RNA-sequence analysis of human B-cells. Genome Res. 2011;21:991\u20138.","journal-title":"Genome Res"},{"key":"1792_CR65","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/00007890-198112000-00002","volume":"32","author":"T Maki","year":"1981","unstructured":"Maki T, Okazaki H, Wood ML, Monaco AP. Suppressor cells in mice bearing intact skin allografts after blood transfusions. Transplantation. 1981;32:463\u20136.","journal-title":"Transplantation"},{"key":"1792_CR66","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.1073\/pnas.1402739111","volume":"111","author":"A Enders","year":"2014","unstructured":"Enders A, Short A, Miosge LA, Bergmann H, Sontani Y, Bertram EM, et al. Zinc-finger protein ZFP318 is essential for expression of IgD, the alternatively spliced Igh product made by mature B lymphocytes. Proc Natl Acad Sci USA. 2014;111:4513\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1792_CR67","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1042\/bst0250383","volume":"25","author":"A Saxon","year":"1997","unstructured":"Saxon A, Diaz-Sanchez D, Zhang K. Regulation of the expression of distinct human secreted IgE proteins produced by alternative RNA splicing. Biochem Soc Trans. 1997;25:383\u20137.","journal-title":"Biochem Soc Trans"},{"key":"1792_CR68","doi-asserted-by":"publisher","first-page":"6162","DOI":"10.1128\/MCB.24.14.6162-6171.2004","volume":"24","author":"C Phillips","year":"2004","unstructured":"Phillips C, Pachikara N, Gunderson SI. U1A inhibits cleavage at the immunoglobulin M heavy-chain secretory poly(A) site by binding between the two downstream GU-rich regions. Mol Cell Biol. 2004;24:6162\u201371.","journal-title":"Mol Cell Biol"},{"key":"1792_CR69","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0092-8674(80)90615-7","volume":"20","author":"FW Alt","year":"1980","unstructured":"Alt FW, Bothwell AL, Knapp M, Siden E, Mather E, Koshland M, et al. Synthesis of secreted and membrane-bound immunoglobulin mu heavy chains is directed by mRNAs that differ at their 3\u2019 ends. Cell. 1980;20:293\u2013301.","journal-title":"Cell"},{"key":"1792_CR70","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1261\/rna.2159506","volume":"12","author":"J Ma","year":"2006","unstructured":"Ma J, Gunderson SI, Phillips C. Non-snRNP U1A levels decrease during mammalian B-cell differentiation and release the IgM secretory poly(A) site from repression. RNA. 2006;12:122\u201332.","journal-title":"RNA"},{"key":"1792_CR71","doi-asserted-by":"publisher","first-page":"S547","DOI":"10.1016\/S0091-6749(00)90059-9","volume":"105","author":"LB Bacharier","year":"2000","unstructured":"Bacharier LB, Geha RS. Molecular mechanisms of IgE regulation. J Allergy Clin Immunol. 2000;105:S547\u201358.","journal-title":"J Allergy Clin Immunol"},{"key":"1792_CR72","doi-asserted-by":"crossref","unstructured":"Yabas M, Elliott H, Hoyne GF. The role of alternative splicing in the control of immune homeostasis and cellular differentiation. Int J Mol Sci. 2016;17:3.","DOI":"10.3390\/ijms17010003"},{"key":"1792_CR73","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/intimm\/dxx026","volume":"29","author":"A Schaub","year":"2017","unstructured":"Schaub A, Glasmacher E. Splicing in immune cells\u2014mechanistic insights and emerging topics. Int Immunol. 2017;29:173\u201381.","journal-title":"Int Immunol"},{"key":"1792_CR74","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/ni.3115","volume":"16","author":"MD Diaz-Mu\u00f1oz","year":"2015","unstructured":"Diaz-Mu\u00f1oz MD, Bell SE, Fairfax K, Monzon-Casanova E, Cunningham AF, Gonzalez-Porta M, et al. The RNA-binding protein HuR is essential for the B cell antibody response. Nat Immunol. 2015;16:415\u201325.","journal-title":"Nat Immunol"},{"key":"1792_CR75","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.molcel.2011.06.007","volume":"43","author":"N Mukherjee","year":"2011","unstructured":"Mukherjee N, Corcoran DL, Nusbaum JD, Reid DW, Georgiev S, Hafner M, et al. Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability. Mol Cell. 2011;43:327\u201339.","journal-title":"Mol Cell"},{"key":"1792_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1593338","volume":"16","author":"J G\u00f3mez-Manr\u00edquez","year":"2025","unstructured":"G\u00f3mez-Manr\u00edquez J, Hern\u00e1ndez-Bello J, Mu\u00f1oz-Valle JF, Sifuentes-Franco S, Graciano-Machuca O, Morales-N\u00fa\u00f1ez JJ. B cell development: transcriptional regulation and immunological mechanisms in homeostasis. Front Immunol. 2025;16:1593338.","journal-title":"Front Immunol"},{"key":"1792_CR77","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood.2023020400","volume":"142","author":"Z Ang","year":"2023","unstructured":"Ang Z, Paruzzo L, Hayer KE, Schmidt C, Torres Diz M, Xu F, et al. Alternative splicing of its 5\u2032-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies. Blood. 2023;142:1724\u201339.","journal-title":"Blood"},{"key":"1792_CR78","doi-asserted-by":"publisher","first-page":"e1004932","DOI":"10.1371\/journal.pgen.1004932","volume":"11","author":"BP O\u2019Connor","year":"2015","unstructured":"O\u2019Connor BP, Danhorn T, De Arras L, Flatley BR, Marcus RA, Farias-Hesson E, et al. Regulation of toll-like receptor signaling by the SF3a mRNA splicing complex. PLoS Genet. 2015;11:e1004932.","journal-title":"PLoS Genet"},{"key":"1792_CR79","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1534\/genetics.113.160499","volume":"197","author":"L De Arras","year":"2014","unstructured":"De Arras L, Laws R, Leach SM, Pontis K, Freedman JH, Schwartz DA, et al. Comparative genomics RNAi screen identifies Eftud2 as a novel regulator of innate immunity. Genetics. 2014;197:485\u201396.","journal-title":"Genetics"},{"key":"1792_CR80","doi-asserted-by":"publisher","first-page":"e1003855","DOI":"10.1371\/journal.pgen.1003855","volume":"9","author":"L De Arras","year":"2013","unstructured":"De Arras L, Alper S. Limiting of the innate immune response by SF3A-dependent control of MyD88 alternative mRNA splicing. PLoS Genet. 2013;9:e1003855.","journal-title":"PLoS Genet"},{"key":"1792_CR81","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.4049\/jimmunol.165.12.6682","volume":"165","author":"KI Iwami","year":"2000","unstructured":"Iwami KI, Matsuguchi T, Masuda A, Kikuchi T, Musikacharoen T, Yoshikai Y. Cutting edge: naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J Immunol. 2000;165:6682\u20136.","journal-title":"J Immunol"},{"key":"1792_CR82","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nature08697","volume":"463","author":"CJ David","year":"2010","unstructured":"David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature. 2010;463:364\u20138.","journal-title":"Nature"},{"key":"1792_CR83","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imm.13304","volume":"163","author":"G Geng","year":"2021","unstructured":"Geng G, Xu C, Peng N, Li Y, Liu J, Wu J, et al. PTBP1 is necessary for dendritic cells to regulate T-cell homeostasis and antitumour immunity. Immunolog. 2021;163:74\u201385.","journal-title":"Immunolog"},{"key":"1792_CR84","first-page":"1731","volume":"7","author":"MS Swanson","year":"1987","unstructured":"Swanson MS, Nakagawa TY, LeVan K, Dreyfuss G. Primary structure of human nuclear ribonucleoprotein particle C proteins: conservation of sequence and domain structures in heterogeneous nuclear RNA, mRNA, and pre-rRNA-binding proteins. Mol Cell Biol. 1987;7:1731\u20139.","journal-title":"Mol Cell Biol"},{"key":"1792_CR85","doi-asserted-by":"publisher","first-page":"9788","DOI":"10.1073\/pnas.86.24.9788","volume":"86","author":"CG Burd","year":"1989","unstructured":"Burd CG, Swanson MS, G\u00f6rlach M, Dreyfuss G. Primary structures of the heterogeneous nuclear ribonucleoprotein A2, B1, and C2 proteins: a diversity of RNA binding proteins is generated by small peptide inserts. Proc Natl Acad Sci. 1989;86:9788\u201392.","journal-title":"Proc Natl Acad Sci"},{"key":"1792_CR86","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.imlet.2013.06.004","volume":"153","author":"R Jia","year":"2013","unstructured":"Jia R, Li X, Yu C, Fan M, Guo J. The splicing factor hnRNP C regulates expression of co-stimulatory molecules CD80 and CD40 in dendritic cells. Immunol Lett. 2013;153:27\u201332.","journal-title":"Immunol Lett"},{"key":"1792_CR87","doi-asserted-by":"crossref","unstructured":"Gowen BG, Chim B, Marceau CD, Greene TT, Burr P, Gonzalez JR, et al. A forward genetic screen reveals novel independent regulators of ULBP1, an activating ligand for natural killer cells. Elife. 2015;4:e08474.","DOI":"10.7554\/eLife.08474"},{"key":"1792_CR88","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccr.2014.07.010","volume":"26","author":"Y Wang","year":"2014","unstructured":"Wang Y, Chen D, Qian H, Tsai YS, Shao S, Liu Q, et al. The splicing factor RBM4 controls apoptosis, proliferation, and migration to suppress tumor progression. Cancer Cell. 2014;26:374\u201389.","journal-title":"Cancer Cell"},{"key":"1792_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10183","volume":"6","author":"J Siewiera","year":"2015","unstructured":"Siewiera J, Gouilly J, Hocine H-R, Cartron G, Levy C, Al-Daccak R, et al. Natural cytotoxicity receptor splice variants orchestrate the distinct functions of human natural killer cell subtypes. Nat Commun. 2015;6:10183.","journal-title":"Nat Commun"},{"key":"1792_CR90","doi-asserted-by":"publisher","first-page":"70912","DOI":"10.18632\/oncotarget.12292","volume":"7","author":"A Shemesh","year":"2016","unstructured":"Shemesh A, Kugel A, Steiner N, Yezersky M, Tirosh D, Edri A, et al. NKp44 and NKp30 splice variant profiles in decidua and tumor tissues: a comparative viewpoint. Oncotarget. 2016;7:70912\u201323.","journal-title":"Oncotarget"},{"key":"1792_CR91","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.3389\/fimmu.2020.02189","volume":"11","author":"K Meissl","year":"2020","unstructured":"Meissl K, Simonovi\u0107 N, Amenitsch L, Witalisz-Siepracka A, Klein K, Lassnig C, et al. STAT1 Isoforms Differentially Regulate NK Cell Maturation and Anti-tumor Activity. Front Immunol. 2020;11:2189.","journal-title":"Front Immunol"},{"key":"1792_CR92","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41588-024-01883-8","volume":"56","author":"C Puttick","year":"2024","unstructured":"Puttick C, Jones TP, Leung MM, Galvez-Cancino F, Liu J, Varas-Godoy M, et al. MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution. Nat Genet. 2024;56:2121\u201331.","journal-title":"Nat Genet"},{"key":"1792_CR93","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41577-025-01208-8","volume":"26","author":"F Huber","year":"2026","unstructured":"Huber F, Bassani-Sternberg M. Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development. Nat Rev Immunol. 2026;26:23\u201334.","journal-title":"Nat Rev Immunol"},{"key":"1792_CR94","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.it.2024.01.009","volume":"45","author":"J Wang","year":"2024","unstructured":"Wang J, Lu Q, Chen X, Aifantis I. Targeting MHC-I inhibitory pathways for cancer immunotherapy. Trends Immunol. 2024;45:177\u201387.","journal-title":"Trends Immunol"},{"key":"1792_CR95","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-021-00486-7","volume":"6","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Qian J, Gu C, Yang Y. Alternative splicing and cancer: a systematic review. Signal Transduct Target Ther. 2021;6:78.","journal-title":"Signal Transduct Target Ther"},{"key":"1792_CR96","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41577-019-0195-7","volume":"19","author":"L Frankiw","year":"2019","unstructured":"Frankiw L, Baltimore D, Li G. Alternative mRNA splicing in cancer immunotherapy. Nat Rev Immunol. 2019;19:675\u201387.","journal-title":"Nat Rev Immunol"},{"key":"1792_CR97","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","volume":"20","author":"K Yang","year":"2023","unstructured":"Yang K, Halima A, Chan TA. Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy. Nat Rev Clin Oncol. 2023;20:604\u201323.","journal-title":"Nat Rev Clin Oncol"},{"key":"1792_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol. 2021;12:636568.","journal-title":"Front Immunol"},{"key":"1792_CR99","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s10020-024-00849-0","volume":"30","author":"Y Sun","year":"2024","unstructured":"Sun Y, Xiong B, Shuai X, Li J, Wang C, Guo J, et al. Downregulation of HNRNPA1 induced neoantigen generation via regulating alternative splicing. Mol Med. 2024;30:85.","journal-title":"Mol Med"},{"key":"1792_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.672356","volume":"12","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Lu M, Qin Y, Gao W, Tao L, Su W, et al. Neoantigen: a new breakthrough in tumor immunotherapy. Front Immunol. 2021;12:672356.","journal-title":"Front Immunol"},{"key":"1792_CR101","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2159-8290.CD-20-1575","volume":"11","author":"RG Gupta","year":"2021","unstructured":"Gupta RG, Li F, Roszik J, Liz\u00e9e G. Exploiting tumor neoantigens to target cancer evolution: current challenges and promising therapeutic approaches. Cancer Discov. 2021;11:1024\u201339.","journal-title":"Cancer Discov"},{"key":"1792_CR102","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1016\/j.cell.2021.05.038","volume":"184","author":"SX Lu","year":"2021","unstructured":"Lu SX, De Neef E, Thomas JD, Sabio E, Rousseau B, Gigoux M, et al. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell. 2021;184:4032\u20134047.e31.","journal-title":"Cell"},{"key":"1792_CR103","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.4049\/jimmunol.1501550","volume":"196","author":"A Reches","year":"2016","unstructured":"Reches A, Nachmani D, Berhani O, Duev-Cohen A, Shreibman D, Ophir Y, et al. HNRNPR regulates the expression of classical and nonclassical MHC class I proteins. J Immunol. 2016;196:4967\u201376.","journal-title":"J Immunol"},{"key":"1792_CR104","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21:298\u2013312.","journal-title":"Nat Rev Cancer"},{"key":"1792_CR105","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2208509120","volume":"120","author":"EM Sroka","year":"2023","unstructured":"Sroka EM, Lavigne M, Pla M, Daskalogianni C, Tovar-Fernandez MC, Prado Martins R, et al. Major histocompatibility class I antigenic peptides derived from translation of pre-mRNAs generate immune tolerance. Proc Natl Acad Sci USA. 2023;120:e2208509120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1792_CR106","doi-asserted-by":"publisher","first-page":"e22939","DOI":"10.1371\/journal.pone.0022939","volume":"6","author":"TG Rodr\u00edguez-Cruz","year":"2011","unstructured":"Rodr\u00edguez-Cruz TG, Liu S, Khalili JS, Whittington M, Zhang M, Overwijk W, et al. Natural splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell responses and boosts anti-tumor immunity. PLoS One. 2011;6:e22939.","journal-title":"PLoS One"},{"key":"1792_CR107","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1084\/jem.20180577","volume":"215","author":"KA Marijt","year":"2018","unstructured":"Marijt KA, Blijleven L, Verdegaal EME, Kester MG, Kowalewski DJ, Rammensee H-G, et al. Identification of non-mutated neoantigens presented by TAP-deficient tumors. J Exp Med. 2018;215:2325\u201337.","journal-title":"J Exp Med"},{"key":"1792_CR108","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12929-022-00879-y","volume":"29","author":"W-C Hsieh","year":"2022","unstructured":"Hsieh W-C, Budiarto BR, Wang Y-F, Lin C-Y, Gwo M-C, So DK, et al. Spatial multi-omics analyses of the tumor immune microenvironment. J Biomed Sci. 2022;29:96.","journal-title":"J Biomed Sci"},{"key":"1792_CR109","doi-asserted-by":"crossref","unstructured":"Rana PS, Ignatz-Hoover JJ, Driscoll JJ. Targeting proteasomes and the MHC class I antigen presentation machinery to treat cancer, infections and age-related diseases. Cancers. 2023;15:5632.","DOI":"10.3390\/cancers15235632"},{"key":"1792_CR110","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2174\/1389203043379774","volume":"5","author":"AJ Rivett","year":"2004","unstructured":"Rivett AJ, Hearn AR. Proteasome function in antigen presentation: immunoproteasome complexes, Peptide production, and interactions with viral proteins. Curr Protein Pept Sci. 2004;5:153\u201361.","journal-title":"Curr Protein Pept Sci"},{"key":"1792_CR111","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1158\/2326-6066.CIR-19-0541","volume":"8","author":"Q Zhao","year":"2020","unstructured":"Zhao Q, Laverdure J-P, Lanoix J, Durette C, C\u00f4t\u00e9 C, Bonneil \u00c9, et al. Proteogenomics uncovers a vast repertoire of shared tumor-specific antigens in ovarian cancer. Cancer Immunol Res. 2020;8:544\u201355.","journal-title":"Cancer Immunol Res"},{"key":"1792_CR112","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40364-025-00877-w","volume":"14","author":"Y Lv","year":"2025","unstructured":"Lv Y, He Y, Dai X, Yang X, Cai Y, Luo R, et al. Alternative splicing: from tumorigenesis to neoantigen-mediated cancer immunotherapy. Biomark Res. 2025;14:4.","journal-title":"Biomark Res"},{"key":"1792_CR113","first-page":"1304","volume":"22","author":"M Zhou","year":"2025","unstructured":"Zhou M, Pan S, Zhang Y, Hu C, Xu Z. Biological mechanism and immune response of MHC-II expression in tumor cells. Cancer Biol Med. 2025;22:1304\u201326.","journal-title":"Cancer Biol Med"},{"key":"1792_CR114","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1038\/s44319-024-00152-3","volume":"25","author":"PG Subramani","year":"2024","unstructured":"Subramani PG, Fraszczak J, Helness A, Estall JL, M\u00f6r\u00f6y T, Di Noia JM. Conserved role of hnRNPL in alternative splicing of epigenetic modifiers enables B cell activation. EMBO Rep. 2024;25:2662\u201397.","journal-title":"EMBO Rep"},{"key":"1792_CR115","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00262-018-2284-z","volume":"68","author":"NB Hassounah","year":"2019","unstructured":"Hassounah NB, Malladi VS, Huang Y, Freeman SS, Beauchamp EM, Koyama S, et al. Identification and characterization of an alternative cancer-derived PD-L1 splice variant. Cancer Immunol Immunother. 2019;68:407\u201320.","journal-title":"Cancer Immunol Immunother"},{"key":"1792_CR116","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1006\/cimm.2000.1649","volume":"201","author":"MK Oaks","year":"2000","unstructured":"Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ. A native soluble form of CTLA-4. Cell Immunol. 2000;201:144\u201353.","journal-title":"Cell Immunol"},{"key":"1792_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-108","volume":"11","author":"S Laurent","year":"2013","unstructured":"Laurent S, Queirolo P, Boero S, Salvi S, Piccioli P, Boccardo S, et al. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-\u03b1 production. J Transl Med. 2013;11:108.","journal-title":"J Transl Med"},{"key":"1792_CR118","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","volume":"229","author":"CE Rudd","year":"2009","unstructured":"Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009;229:12\u201326.","journal-title":"Immunol Rev"},{"key":"1792_CR119","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.immuni.2024.01.019","volume":"57","author":"R Ding","year":"2024","unstructured":"Ding R, Yu X, Hu Z, Dong Y, Huang H, Zhang Y, et al. Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells. Immunity. 2024;57:528\u2013540.e6.","journal-title":"Immunity"},{"key":"1792_CR120","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00262-018-2258-1","volume":"68","author":"MP Pistillo","year":"2019","unstructured":"Pistillo MP, Fontana V, Morabito A, Dozin B, Laurent S, Carosio R, et al. Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. Cancer Immunol Immunother. 2019;68:97\u2013107.","journal-title":"Cancer Immunol Immunother"},{"key":"1792_CR121","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12865-021-00422-y","volume":"22","author":"J Liu","year":"2021","unstructured":"Liu J, Tian X, Wang Y, Kang X, Song W. Soluble cytotoxic T-lymphocyte-associated antigen 4 (sCTLA-4) as a potential biomarker for diagnosis and evaluation of the prognosis in Glioma. BMC Immunol. 2021;22:33.","journal-title":"BMC Immunol"},{"key":"1792_CR122","doi-asserted-by":"crossref","unstructured":"Clare P, Al-Fatyan F, Risheh B, Nellany K, Ward FJ, Abu-Eid R. A novel role for the soluble isoform of CTLA-4 in normal, dysplastic and neoplastic oral and oropharyngeal epithelia. Cancers. 2023;15:1696.","DOI":"10.3390\/cancers15061696"},{"key":"1792_CR123","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.clbc.2019.03.008","volume":"19","author":"Y Li","year":"2019","unstructured":"Li Y, Cui X, Yang Y-J, Chen Q-Q, Zhong L, Zhang T, et al. Serum sPD-1 and sPD-L1 as biomarkers for evaluating the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients. Clin Breast Cancer. 2019;19:326\u2013332.e1.","journal-title":"Clin Breast Cancer"},{"key":"1792_CR124","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/2326-6066.CIR-16-0329","volume":"5","author":"J Zhou","year":"2017","unstructured":"Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao F, Lee S, Liao X, et al. Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade. Cancer Immunol Res. 2017;5:480\u201392.","journal-title":"Cancer Immunol Res"},{"key":"1792_CR125","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1084\/jem.20180870","volume":"216","author":"B Gong","year":"2019","unstructured":"Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019;216:982\u20131000.","journal-title":"J Exp Med"},{"key":"1792_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156532","volume":"176","author":"S Han","year":"2024","unstructured":"Han S, Zhang Y, Yuan J, Wu Y, Zhou Y, Zhou Y, et al. sPD-L1 and sPD-L2 in plasma of patients with lung cancer and their clinical significance. Cytokine. 2024;176:156532.","journal-title":"Cytokine"},{"key":"1792_CR127","first-page":"934","volume":"26","author":"M Chivu-Economescu","year":"2023","unstructured":"Chivu-Economescu M, Herlea V, Dima S, Sorop A, Pechianu C, Procop A, et al. Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients. Gastric Cancer J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2023;26:934\u201346.","journal-title":"Gastric Cancer J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"key":"1792_CR128","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/1097-0142(20010715)92:2<369::AID-CNCR1332>3.0.CO;2-U","volume":"92","author":"S Ugurel","year":"2001","unstructured":"Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U. Soluble human leukocyte antigen\u2013G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer. 2001;92:369\u201376.","journal-title":"Cancer"},{"key":"1792_CR129","doi-asserted-by":"publisher","first-page":"7383","DOI":"10.1007\/s13277-014-2150-3","volume":"35","author":"H Jiang","year":"2014","unstructured":"Jiang H, Zhao W, Shao W. Prognostic value of CD44 and CD44v6 expression in patients with non-small cell lung cancer: meta-analysis. Tumour Biol J Int Soc Oncodev Biol Med. 2014;35:7383\u20139.","journal-title":"Tumour Biol J Int Soc Oncodev Biol Med"},{"key":"1792_CR130","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1158\/0008-5472.CAN-13-2309","volume":"74","author":"WM Lau","year":"2014","unstructured":"Lau WM, Teng E, Chong HS, Lopez KAP, Tay AYL, Salto-Tellez M, et al. CD44v8-10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res. 2014;74:2630\u201341.","journal-title":"Cancer Res"},{"key":"1792_CR131","doi-asserted-by":"crossref","unstructured":"Teles SP, Oliveira P, Ferreira M, Carvalho J, Ferreira P, Oliveira C. Integrated analysis of structural variation and RNA expression of FGFR2 and its splicing modulator ESRP1 highlight the ESRP1(amp)-FGFR2(norm)-FGFR2-IIIc(high) axis in diffuse gastric cancer. Cancers. 2019;12:70.","DOI":"10.3390\/cancers12010070"},{"key":"1792_CR132","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1365-3083.2007.02009.x","volume":"66","author":"M Kakoulidou","year":"2007","unstructured":"Kakoulidou M, Giscombe R, Zhao X, Lefvert AK, Wang X. Human Soluble CD80 is generated by alternative splicing, and recombinant soluble CD80 binds to CD28 and CD152 influencing T-cell activation. Scand J Immunol. 2007;66:529\u201337.","journal-title":"Scand J Immunol"},{"key":"1792_CR133","doi-asserted-by":"crossref","unstructured":"Bessa C, Matos P, Jordan P, Gon\u00e7alves V. Alternative splicing: expanding the landscape of cancer biomarkers and therapeutics. Int J Mol Sci. 2020;21:9032.","DOI":"10.3390\/ijms21239032"},{"key":"1792_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01844-5","volume":"22","author":"J Li","year":"2023","unstructured":"Li J, Xiao Z, Wang D, Jia L, Nie S, Zeng X, et al. The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells. Mol Cancer. 2023;22:141.","journal-title":"Mol Cancer"},{"key":"1792_CR135","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.molmed.2015.11.005","volume":"22","author":"M Salton","year":"2016","unstructured":"Salton M, Misteli T. Small molecule modulators of Pre-mRNA splicing in cancer therapy. Trends Mol Med. 2016;22:28\u201337.","journal-title":"Trends Mol Med"},{"key":"1792_CR136","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41586-023-06277-0","volume":"619","author":"J Kim","year":"2023","unstructured":"Kim J, Woo S, de Gusmao CM, Zhao B, Chin DH, DiDonato RL, et al. A framework for individualized splice-switching oligonucleotide therapy. Nature. 2023;619:828\u201336.","journal-title":"Nature"},{"key":"1792_CR137","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nrg3052","volume":"12","author":"A Kalsotra","year":"2011","unstructured":"Kalsotra A, Cooper TA. Functional consequences of developmentally regulated alternative splicing. Nat Rev Genet. 2011;12:715\u201329.","journal-title":"Nat Rev Genet"},{"key":"1792_CR138","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ccell.2022.12.002","volume":"41","author":"E Wang","year":"2023","unstructured":"Wang E, Pineda JMB, Kim WJ, Chen S, Bourcier J, Stahl M, et al. Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia. Cancer Cell. 2023;41:164\u2013180.e8.","journal-title":"Cancer Cell"},{"key":"1792_CR139","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13046-021-01978-8","volume":"40","author":"J-X Du","year":"2021","unstructured":"Du J-X, Luo Y-H, Zhang S-J, Wang B, Chen C, Zhu G-Q, et al. Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1. J Exp Clin Cancer Res. 2021;40:171.","journal-title":"J Exp Clin Cancer Res"},{"key":"1792_CR140","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/nature07509","volume":"456","author":"ET Wang","year":"2008","unstructured":"Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, et al. Alternative isoform regulation in human tissue transcriptomes. Nature. 2008;456:470\u20136.","journal-title":"Nature"},{"key":"1792_CR141","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1038\/onc.2015.318","volume":"35","author":"A Sveen","year":"2016","unstructured":"Sveen A, Kilpinen S, Ruusulehto A, Lothe RA, Skotheim RI. Aberrant RNA splicing in cancer: expression changes and driver mutations of splicing factor genes. Oncogene. 2016;35:2413\u201327.","journal-title":"Oncogene"},{"key":"1792_CR142","doi-asserted-by":"publisher","first-page":"D124","DOI":"10.1093\/nar\/gkad745","volume":"52","author":"Q Shi","year":"2024","unstructured":"Shi Q, Li X, Liu Y, Chen Z, He X. FLIBase: a comprehensive repository of full-length isoforms across human cancers and tissues. Nucleic Acids Res. 2024;52:D124\u201333.","journal-title":"Nucleic Acids Res"},{"key":"1792_CR143","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2221116120","volume":"120","author":"Y Pan","year":"2023","unstructured":"Pan Y, Phillips JW, Zhang BD, Noguchi M, Kutschera E, McLaughlin J, et al. IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing. Proc Natl Acad Sci USA. 2023;120:e2221116120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1792_CR144","doi-asserted-by":"publisher","first-page":"8926","DOI":"10.1038\/s41467-024-53296-0","volume":"15","author":"H Xu","year":"2024","unstructured":"Xu H, Hu R, Dong X, Kuang L, Zhang W, Tu C, et al. ImmuneApp for HLA-I epitope prediction and immunopeptidome analysis. Nat Commun. 2024;15:8926.","journal-title":"Nat Commun"},{"key":"1792_CR145","doi-asserted-by":"crossref","unstructured":"Wang Y, Wengler J, Fang Y, Zhou J, Ruan H, Zhang Z, et al. Characterization of tumor antigens from multi-omics data: computational approaches and resources. Genomics, Proteomics, Bioinformatics. 2025;23:qzaf001.","DOI":"10.1093\/gpbjnl\/qzaf001"},{"key":"1792_CR146","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1158\/2767-9764.CRC-23-0309","volume":"4","author":"T Palmer","year":"2024","unstructured":"Palmer T, Kessler MD, Shao XM, Balan A, Yarchoan M, Zaidi N, et al. SpliceMutr enables pan-cancer analysis of splicing-derived neoantigen burden in tumors. Cancer Res Commun. 2024;4:3137\u201350.","journal-title":"Cancer Res Commun"},{"key":"1792_CR147","doi-asserted-by":"crossref","unstructured":"Bendik J, Castro A, Califano J, Carter H, Guo T. Identifying strong neoantigen mhc-i\/ii binding candidates for targeted immunotherapy with SINE. Int J Mol Sci. 2024;26:205.","DOI":"10.3390\/ijms26010205"},{"key":"1792_CR148","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade2886","volume":"16","author":"G Li","year":"2024","unstructured":"Li G, Mahajan S, Ma S, Jeffery ED, Zhang X, Bhattacharjee A, et al. Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy. Sci Transl Med. 2024;16:eade2886.","journal-title":"Sci Transl Med"},{"key":"1792_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-015-0168-9","volume":"7","author":"H Dvinge","year":"2015","unstructured":"Dvinge H, Bradley RK. Widespread intron retention diversifies most cancer transcriptomes. Genome Med. 2015;7:45.","journal-title":"Genome Med"},{"key":"1792_CR150","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.868664","volume":"12","author":"AJ Murphy","year":"2022","unstructured":"Murphy AJ, Li AH, Li P, Sun H. Therapeutic targeting of alternative splicing: a new frontier in cancer treatment. Front Oncol. 2022;12:868664.","journal-title":"Front Oncol"},{"key":"1792_CR151","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.gde.2017.10.010","volume":"48","author":"AA Agrawal","year":"2018","unstructured":"Agrawal AA, Yu L, Smith PG, Buonamici S. Targeting splicing abnormalities in cancer. Curr Opin Genet Dev. 2018;48:67\u201374.","journal-title":"Curr Opin Genet Dev"},{"key":"1792_CR152","doi-asserted-by":"publisher","first-page":"14497","DOI":"10.1021\/acs.jmedchem.3c00733","volume":"66","author":"JP Beard","year":"2023","unstructured":"Beard JP, Bressin RK, Markaj PL, Schmitz JC, Koide K. Synthesis and conformational analysis of FR901464-based RNA splicing modulators and their synergism in drug-resistant cancers. J Med Chem. 2023;66:14497\u2013512.","journal-title":"J Med Chem"},{"key":"1792_CR153","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.chembiol.2021.03.002","volume":"28","author":"R Yoshimoto","year":"2021","unstructured":"Yoshimoto R, Chhipi-Shrestha JK, Schneider-Poetsch T, Furuno M, Burroughs AM, Noma S, et al. Spliceostatin A interaction with SF3B limits U1 snRNP availability and causes premature cleavage and polyadenylation. Cell Chem Biol. 2021;28:1356\u20131365.e4.","journal-title":"Cell Chem Biol"},{"key":"1792_CR154","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nchembio.2007.18","volume":"3","author":"D Kaida","year":"2007","unstructured":"Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M, Ishigami K, et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol. 2007;3:576\u201383.","journal-title":"Nat Chem Biol"},{"key":"1792_CR155","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s10637-013-0046-5","volume":"32","author":"DS Hong","year":"2014","unstructured":"Hong DS, Kurzrock R, Naing A, Wheler JJ, Falchook GS, Schiffman JS, et al. A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest N Drugs. 2014;32:436\u201344.","journal-title":"Invest N Drugs"},{"key":"1792_CR156","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1101\/gad.2009411","volume":"25","author":"EG Folco","year":"2011","unstructured":"Folco EG, Coil KE, Reed R. The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region. Genes Dev. 2011;25:440\u20134.","journal-title":"Genes Dev"},{"key":"1792_CR157","doi-asserted-by":"publisher","first-page":"27524","DOI":"10.1074\/jbc.M115.673210","volume":"290","author":"KA Effenberger","year":"2015","unstructured":"Effenberger KA, James RC, Urabe VK, Dickey BJ, Linington RG, Jurica MS. The natural product N-palmitoyl-l-leucine selectively inhibits late assembly of human spliceosomes. J Biol Chem. 2015;290:27524\u201331.","journal-title":"J Biol Chem"},{"key":"1792_CR158","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202304895","volume":"10","author":"Z Wu","year":"2023","unstructured":"Wu Z, Zuo X, Zhang W, Li Y, Gui R, Leng J, et al. m6A-modified circTET2 interacting with HNRNPC regulates fatty acid oxidation to promote the proliferation of chronic lymphocytic leukemia. Adv Sci. 2023;10:e2304895.","journal-title":"Adv Sci"},{"key":"1792_CR159","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ccell.2019.05.014","volume":"36","author":"A Fedoriw","year":"2019","unstructured":"Fedoriw A, Rajapurkar SR, O\u2019Brien S, Gerhart SV, Mitchell LH, Adams ND, et al. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. Cancer Cell. 2019;36:100\u2013114.e25.","journal-title":"Cancer Cell"},{"key":"1792_CR160","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/bjc.2014.342","volume":"111","author":"MV Gammons","year":"2014","unstructured":"Gammons MV, Lucas R, Dean R, Coupland SE, Oltean S, Bates DO. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. Br J Cancer. 2014;111:477\u201385.","journal-title":"Br J Cancer"},{"key":"1792_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115161","volume":"203","author":"GA Moreira","year":"2022","unstructured":"Moreira GA, Caetano MMM, do Vale JA, de Paiva JC, Gon\u00e7alves VHS, Almeida AA, et al. The SRPK inhibitor N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl) isonicotinamide (SRPIN340) increases the immune response against metastatic melanoma in mice. Biochem Pharmacol. 2022;203:115161.","journal-title":"Biochem Pharmacol"},{"key":"1792_CR162","first-page":"6876","volume":"61","author":"B Pilch","year":"2001","unstructured":"Pilch B, Allemand E, Facompr\u00e9 M, Bailly C, Riou JF, Soret J, et al. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Cancer Res. 2001;61:6876\u201384.","journal-title":"Cancer Res"},{"key":"1792_CR163","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21204-5","volume":"12","author":"P Sachamitr","year":"2021","unstructured":"Sachamitr P, Ho JC, Ciamponi FE, Ba-Alawi W, Coutinho FJ, Guilhamon P, et al. PRMT5 inhibition disrupts splicing and stemness in glioblastoma. Nat Commun. 2021;12:979.","journal-title":"Nat Commun"},{"key":"1792_CR164","doi-asserted-by":"publisher","first-page":"17990","DOI":"10.1073\/pnas.1901323116","volume":"116","author":"S AbuHammad","year":"2019","unstructured":"AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen H, et al. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4\/6 inhibitors in melanoma. Proc Natl Acad Sci USA. 2019;116:17990\u20138000.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1792_CR165","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1535-7163.MCT-21-0620","volume":"21","author":"K Jensen-Pergakes","year":"2022","unstructured":"Jensen-Pergakes K, Tatlock J, Maegley KA, McAlpine IJ, McTigue M, Xie T, et al. SAM-competitive PRMT5 inhibitor PF-06939999 demonstrates antitumor activity in splicing dysregulated nsclc with decreased liability of drug resistance. Mol Cancer Ther. 2022;21:3\u201315.","journal-title":"Mol Cancer Ther"},{"key":"1792_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102961","volume":"9","author":"J Rodon","year":"2024","unstructured":"Rodon J, Rodriguez E, Maitland ML, Tsai FY-C, Socinski MA, Berlin JD, et al. A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations. ESMO open. 2024;9:102961.","journal-title":"ESMO open"},{"key":"1792_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107390","volume":"134","author":"T Haque","year":"2023","unstructured":"Haque T, Cadenas FL, Xicoy B, Alfonso-Pierola A, Platzbecker U, Avivi I, et al. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes. Leuk Res. 2023;134:107390.","journal-title":"Leuk Res"},{"key":"1792_CR168","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1002\/hep.31864","volume":"74","author":"Y Luo","year":"2021","unstructured":"Luo Y, Gao Y, Liu W, Yang Y, Jiang J, Wang Y, et al. Myelocytomatosis-protein arginine N-methyltransferase 5 axis defines the tumorigenesis and immune response in hepatocellular carcinoma. Hepatology. 2021;74:1932\u201351.","journal-title":"Hepatology"},{"key":"1792_CR169","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1158\/1535-7163.MCT-21-0367","volume":"20","author":"D Brehmer","year":"2021","unstructured":"Brehmer D, Beke L, Wu T, Millar HJ, Moy C, Sun W, et al. Discovery and Pharmacological characterization of JNJ-64619178, a novel small-molecule inhibitor of PRMT5 with potent antitumor activity. Mol Cancer Ther. 2021;20:2317\u201328.","journal-title":"Mol Cancer Ther"},{"key":"1792_CR170","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/nm.4097","volume":"22","author":"SC-W Lee","year":"2016","unstructured":"Lee SC-W, Dvinge H, Kim E, Cho H, Micol J-B, Chung YR, et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med. 2016;22:672\u20138.","journal-title":"Nat Med"},{"key":"1792_CR171","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nm.4493","volume":"24","author":"M Seiler","year":"2018","unstructured":"Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018;24:497\u2013504.","journal-title":"Nat Med"},{"key":"1792_CR172","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/leu.2015.286","volume":"30","author":"M Larrayoz","year":"2016","unstructured":"Larrayoz M, Blakemore SJ, Dobson RC, Blunt MD, Rose-Zerilli MJJ, Walewska R, et al. The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1. Leukemia. 2016;30:351\u201360.","journal-title":"Leukemia"},{"key":"1792_CR173","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ebiom.2018.12.025","volume":"39","author":"R Sciarrillo","year":"2019","unstructured":"Sciarrillo R, Wojtuszkiewicz A, El Hassouni B, Funel N, Gandellini P, Lagerweij T, et al. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. EBioMedicine. 2019;39:215\u201325.","journal-title":"EBioMedicine"},{"key":"1792_CR174","doi-asserted-by":"crossref","unstructured":"Han T, Goralski M, Gaskill N, Capota E, Kim J, Ting TC, et al. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science. 2017;356:eaal3755.","DOI":"10.1126\/science.aal3755"},{"key":"1792_CR175","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28907-3","volume":"13","author":"A Nijhuis","year":"2022","unstructured":"Nijhuis A, Sikka A, Yogev O, Herendi L, Balcells C, Ma Y, et al. Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma. Nat Commun. 2022;13:1380.","journal-title":"Nat Commun"},{"key":"1792_CR176","doi-asserted-by":"publisher","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-13-0485","volume":"19","author":"FALM Eskens","year":"2013","unstructured":"Eskens FALM, Ramos FJ, Burger H, O\u2019Brien JP, Piera A, de Jonge MJA, et al. Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. Clin Cancer Res J Am Assoc Cancer Res. 2013;19:6296\u2013304.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"1792_CR177","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14060","volume":"8","author":"CL Shirai","year":"2017","unstructured":"Shirai CL, White BS, Tripathi M, Tapia R, Ley JN, Ndonwi M, et al. Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nat Commun. 2017;8:14060.","journal-title":"Nat Commun"},{"key":"1792_CR178","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1038\/s41375-021-01328-9","volume":"35","author":"DP Steensma","year":"2021","unstructured":"Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, et al. Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021;35:3542\u201350.","journal-title":"Leukemia"},{"key":"1792_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2025.107735","volume":"156","author":"JM Foran","year":"2025","unstructured":"Foran JM, Sanz GF, Watts JM, Brunner AM, Fossard G, Della Porta MG, et al. Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B\u20118800 in lower-risk myelodysplastic syndrome. Leuk Res. 2025;156:107735.","journal-title":"Leuk Res"},{"key":"1792_CR180","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1002\/cncr.31398","volume":"124","author":"R Assi","year":"2018","unstructured":"Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, et al. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018;124:2758\u201365.","journal-title":"Cancer"},{"key":"1792_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113307","volume":"42","author":"Y Xu","year":"2023","unstructured":"Xu Y, Spear S, Ma Y, Lorentzen MP, Gruet M, McKinney F, et al. Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma. Cell Rep. 2023;42:113307.","journal-title":"Cell Rep"},{"key":"1792_CR182","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody\u2013drug conjugates. Nat Rev Clin Oncol. 2024;21:203\u201323.","journal-title":"Nat Rev Clin Oncol"},{"key":"1792_CR183","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41568-025-00847-2","volume":"25","author":"VF Gomerdinger","year":"2025","unstructured":"Gomerdinger VF, Nabar N, Hammond PT. Advancing engineering design strategies for targeted cancer nanomedicine. Nat Rev Cancer. 2025;25:657\u201383.","journal-title":"Nat Rev Cancer"},{"key":"1792_CR184","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","volume":"25","author":"A Zippelius","year":"2025","unstructured":"Zippelius A, Tolaney SM, Tarantino P, Balthasar JP, Thurber GM. Unveiling the molecular and immunological drivers of antibody\u2013drug conjugates in cancer treatment. Nat Rev Cancer. 2025;25:925\u201344.","journal-title":"Nat Rev Cancer"},{"key":"1792_CR185","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1073\/pnas.75.1.280","volume":"75","author":"PC Zamecnik","year":"1978","unstructured":"Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA. 1978;75:280\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1792_CR186","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113834","volume":"178","author":"A Gupta","year":"2021","unstructured":"Gupta A, Andresen JL, Manan RS, Langer R. Nucleic acid delivery for therapeutic applications. Adv Drug Deliv Rev. 2021;178:113834.","journal-title":"Adv Drug Deliv Rev"},{"key":"1792_CR187","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723\u201332.","journal-title":"N Engl J Med"},{"key":"1792_CR188","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1172\/JCI82534","volume":"126","author":"M Dewaele","year":"2016","unstructured":"Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo SX, Low DHP, et al. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J Clin Investig. 2016;126:68\u201384.","journal-title":"J Clin Investig"},{"key":"1792_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111280","volume":"126","author":"X Wang","year":"2024","unstructured":"Wang X, Yan L, Guo J, Jia R. An anti-PD-1 antisense oligonucleotide promotes the expression of soluble PD-1 by blocking the interaction between SRSF3 and an exonic splicing enhancer of PD-1 exon 3. Int Immunopharmacol. 2024;126:111280.","journal-title":"Int Immunopharmacol"},{"key":"1792_CR190","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13046-021-02001-w","volume":"40","author":"Z Dou","year":"2021","unstructured":"Dou Z, Zhao D, Chen X, Xu C, Jin X, Zhang X, et al. Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation. J Exp Clin Cancer Res. 2021;40:194.","journal-title":"J Exp Clin Cancer Res"},{"key":"1792_CR191","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/humu.23390","volume":"39","author":"A Baert","year":"2018","unstructured":"Baert A, Machackova E, Coene I, Cremin C, Turner K, Portigal-Todd C, et al. Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11. Hum Mutat. 2018;39:515\u201326.","journal-title":"Hum Mutat"},{"key":"1792_CR192","doi-asserted-by":"publisher","first-page":"4903","DOI":"10.1158\/1078-0432.CCR-12-1100","volume":"18","author":"O Anczuk\u00f3w","year":"2012","unstructured":"Anczuk\u00f3w O, Buisson M, L\u00e9on\u00e9 M, Coutanson C, Lasset C, Calender A, et al. BRCA2 deep intronic mutation causing activation of a cryptic exon: opening toward a new preventive therapeutic strategy. Clin Cancer Res J Am Assoc Cancer Res. 2012;18:4903\u20139.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"1792_CR193","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1038\/onc.2015.270","volume":"35","author":"S Calabretta","year":"2016","unstructured":"Calabretta S, Bielli P, Passacantilli I, Pilozzi E, Fendrich V, Capurso G, et al. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Oncogene. 2016;35:2031\u20139.","journal-title":"Oncogene"},{"key":"1792_CR194","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34042-w","volume":"13","author":"Z Wang","year":"2022","unstructured":"Wang Z, Wang S, Qin J, Zhang X, Lu G, Liu H, et al. Splicing factor BUD31 promotes ovarian cancer progression through sustaining the expression of anti-apoptotic BCL2L12. Nat Commun. 2022;13:6246.","journal-title":"Nat Commun"},{"key":"1792_CR195","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09523-0","volume":"10","author":"P Denichenko","year":"2019","unstructured":"Denichenko P, Mogilevsky M, Cl\u00e9ry A, Welte T, Biran J, Shimshon O, et al. Specific inhibition of splicing factor activity by decoy RNA oligonucleotides. Nat Commun. 2019;10:1590.","journal-title":"Nat Commun"},{"key":"1792_CR196","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01518-8","volume":"21","author":"S-W Wang","year":"2022","unstructured":"Wang S-W, Gao C, Zheng Y-M, Yi L, Lu J-C, Huang X-Y, et al. Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer. Mol Cancer. 2022;21:57.","journal-title":"Mol Cancer"},{"key":"1792_CR197","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1016\/j.ymthe.2018.07.024","volume":"26","author":"D Benati","year":"2018","unstructured":"Benati D, Miselli F, Cocchiarella F, Patrizi C, Carretero M, Baldassarri S, et al. CRISPR\/Cas9-mediated in situ correction of LAMB3 gene in keratinocytes derived from a junctional epidermolysis bullosa patient. Mol Ther. 2018;26:2592\u2013603.","journal-title":"Mol Ther"},{"key":"1792_CR198","first-page":"812","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang T-H, et al. The immune landscape of cancer. Immunology. 2018;48:812\u2013830.e14.","journal-title":"Immunology"},{"key":"1792_CR199","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.3390\/biom5032073","volume":"5","author":"F Shakola","year":"2015","unstructured":"Shakola F, Suri P, Ruggiu M. Splicing regulation of pro-inflammatory cytokines and chemokines: at the interface of the neuroendocrine and immune systems. Biomolecules. 2015;5:2073\u2013100.","journal-title":"Biomolecules"},{"key":"1792_CR200","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1158\/1078-0432.CCR-20-0184","volume":"26","author":"G Anande","year":"2020","unstructured":"Anande G, Deshpande NP, Mareschal S, Batcha AMN, Hampton HR, Herold T, et al. RNA splicing alterations induce a cellular stress response associated with poor prognosis in acute myeloid leukemia. Clin Cancer Res J Am Assoc Cancer Res. 2020;26:3597\u2013607.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"1792_CR201","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.matbio.2020.06.003","volume":"93","author":"SP Giblin","year":"2020","unstructured":"Giblin SP, Schwenzer A, Midwood KS. Alternative splicing controls cell lineage-specific responses to endogenous innate immune triggers within the extracellular matrix. Matrix Biol. 2020;93:95\u2013114.","journal-title":"Matrix Biol"},{"key":"1792_CR202","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X, et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023;22:48.","journal-title":"Mol Cancer"},{"key":"1792_CR203","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s00262-007-0343-y","volume":"56","author":"DO Croci","year":"2007","unstructured":"Croci DO, Zacar\u00edas Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother. 2007;56:1687\u2013700.","journal-title":"Cancer Immunol Immunother"},{"key":"1792_CR204","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.763886","volume":"11","author":"J Wu","year":"2021","unstructured":"Wu J, Sun Y, Li J, Ai M, You L, Shi J, et al. Analysis of prognostic alternative splicing reveals the landscape of immune microenvironment in thyroid cancer. Front Oncol. 2021;11:763886.","journal-title":"Front Oncol"},{"key":"1792_CR205","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1038\/s41388-018-0129-z","volume":"37","author":"F Roudnicky","year":"2018","unstructured":"Roudnicky F, Yoon SY, Poghosyan S, Schwager S, Poyet C, Vella G, et al. Alternative transcription of a shorter, non-anti-angiogenic thrombospondin-2 variant in cancer-associated blood vessels. Oncogene. 2018;37:2573\u201385.","journal-title":"Oncogene"},{"key":"1792_CR206","doi-asserted-by":"crossref","unstructured":"Peach CJ, Mignone VW, Arruda MA, Alcobia DC, Hill SJ, Kilpatrick LE, et al. Molecular pharmacology of VEGF-A isoforms: binding and signalling at VEGFR2. Int J Mol Sci. 2018;19:1264.","DOI":"10.3390\/ijms19041264"},{"key":"1792_CR207","doi-asserted-by":"publisher","first-page":"10948","DOI":"10.1158\/0008-5472.CAN-07-1436","volume":"67","author":"J-N Rybak","year":"2007","unstructured":"Rybak J-N, Roesli C, Kaspar M, Villa A, Neri D. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res. 2007;67:10948\u201357.","journal-title":"Cancer Res"},{"key":"1792_CR208","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4049098","volume":"2017","author":"LM Castello","year":"2017","unstructured":"Castello LM, Raineri D, Salmi L, Clemente N, Vaschetto R, Quaglia M, et al. Osteopontin at the crossroads of inflammation and tumor progression. Mediators Inflamm. 2017;2017:4049098.","journal-title":"Mediators Inflamm"},{"key":"1792_CR209","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.bbcan.2017.02.005","volume":"1868","author":"MA Briones-Orta","year":"2017","unstructured":"Briones-Orta MA, Avenda\u00f1o-V\u00e1zquez SE, Aparicio-Bautista DI, Coombes JD, Weber GF, Syn W-K. Osteopontin splice variants and polymorphisms in cancer progression and prognosis. Biochim Biophys acta Rev cancer. 2017;1868:93\u2013108.","journal-title":"Biochim Biophys acta Rev cancer"},{"key":"1792_CR210","doi-asserted-by":"crossref","unstructured":"Holzmann K, Grunt T, Heinzle C, Sampl S, Steinhoff H, Reichmann N, et al. Alternative splicing of fibroblast growth factor receptor igiii loops in cancer. J Nucleic Acids. 2012;2012:950508.","DOI":"10.1155\/2012\/950508"},{"key":"1792_CR211","doi-asserted-by":"crossref","unstructured":"Ikeda-Iwabu Y, Taniyama Y, Katsuragi N, Sanada F, Koibuchi N, Shibata K, et al. Periostin short fragment with exon 17 via aberrant alternative splicing is required for breast cancer growth and metastasis. Cells. 2021;10:892.","DOI":"10.3390\/cells10040892"},{"key":"1792_CR212","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1089\/107999099313947","volume":"19","author":"A Korte","year":"1999","unstructured":"Korte A, M\u00f6ricke A, Beyermann B, K\u00f6chling J, Taube T, Kebelmann-Betzing C, et al. Extensive alternative splicing of interleukin-7 in malignant hematopoietic cells: implication of distinct isoforms in modulating IL-7 activity. J Inter Cytokine Res J Int Soc Inter Cytokine Res. 1999;19:495\u2013503.","journal-title":"J Inter Cytokine Res J Int Soc Inter Cytokine Res"},{"key":"1792_CR213","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.7150\/ijbs.82317","volume":"19","author":"Y Yang","year":"2023","unstructured":"Yang Y, Li J, Lei W, Wang H, Ni Y, Liu Y, et al. CXCL12-CXCR4\/CXCR7 axis in cancer: from mechanisms to clinical applications. Int J Biol Sci. 2023;19:3341\u201359.","journal-title":"Int J Biol Sci"},{"key":"1792_CR214","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1093\/intimm\/11.12.1965","volume":"11","author":"S Kruse","year":"1999","unstructured":"Kruse S, Forster J, Kuehr J, Deichmann KA. Characterization of the membrane-bound and a soluble form of human IL-4 receptor \u03b1 produced by alternative splicing. Int Immunol. 1999;11:1965\u201370.","journal-title":"Int Immunol"},{"key":"1792_CR215","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/carcin\/bgv172","volume":"37","author":"B Heinhuis","year":"2016","unstructured":"Heinhuis B, Plantinga T, Semango G, K\u00fcsters B, Netea M, Dinarello C, et al. Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines. Carcinogenesis. 2016;37:197\u2013205.","journal-title":"Carcinogenesis"},{"key":"1792_CR216","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1158\/2159-8290.CD-23-0282","volume":"13","author":"M Zhang","year":"2023","unstructured":"Zhang M, Huang Y, Pan J, Sang C, Lin Y, Dong L, et al. An inflammatory checkpoint generated by IL1RN splicing offers therapeutic opportunity for kras-mutant intrahepatic cholangiocarcinoma. Cancer Discov. 2023;13:2248\u201369.","journal-title":"Cancer Discov"},{"key":"1792_CR217","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202406633","volume":"11","author":"C Zhao","year":"2024","unstructured":"Zhao C, Zhao J-W, Zhang Y-H, Zhu Y, Yang Z-Y, Liu S-L, et al. PTBP3 mediates IL-18 exon skipping to promote immune escape in gallbladder cancer. Adv Sci. 2024;11:e2406633.","journal-title":"Adv Sci"},{"key":"1792_CR218","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.immuni.2020.12.012","volume":"54","author":"CA Ishak","year":"2021","unstructured":"Ishak CA, Loo Yau H, De Carvalho DD. Spliceosome-targeted therapies induce dsRNA responses. Immunity. 2021;54:11\u20133.","journal-title":"Immunity"},{"key":"1792_CR219","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116384","volume":"44","author":"X Jiang","year":"2025","unstructured":"Jiang X, Ma X, Zhou Y, Liu X, Zhang T, Kim W, et al. Spliceosome inhibition induces Z-RNA and ZBP1-driven cell death in small cell lung cancer. Cell Rep. 2025;44:116384.","journal-title":"Cell Rep"},{"key":"1792_CR220","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41573-025-01273-7","volume":"25","author":"E Gon\u00e7alves","year":"2026","unstructured":"Gon\u00e7alves E, Ryan CJ, Adams DJ. Synthetic lethality in cancer drug discovery: challenges and opportunities. Nat Rev Drug Discov. 2026;25:22\u201338.","journal-title":"Nat Rev Drug Discov"},{"key":"1792_CR221","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1158\/2326-6066.CIR-23-0083","volume":"11","author":"T Yao","year":"2023","unstructured":"Yao T, Zhang Z, Li Q, Huang R, Hong Y, Li C, et al. Long-read sequencing reveals alternative splicing-driven, shared immunogenic neoepitopes regardless of SF3B1 status in uveal melanoma. Cancer Immunol Res. 2023;11:1671\u201387.","journal-title":"Cancer Immunol Res"},{"key":"1792_CR222","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-023-01226-y","volume":"15","author":"Q Sun","year":"2023","unstructured":"Sun Q, Han Y, He J, Wang J, Ma X, Ning Q, et al. Long-read sequencing reveals the landscape of aberrant alternative splicing and novel therapeutic target in colorectal cancer. Genome Med. 2023;15:76.","journal-title":"Genome Med"},{"key":"1792_CR223","doi-asserted-by":"crossref","unstructured":"Liu J, Lin C-X, Zhang X, Li Z, Huang W, Liu J, et al. Computational approaches for detecting disease-associated alternative splicing events. Brief Bioinform. 2023;24:bbad106.","DOI":"10.1093\/bib\/bbad106"},{"key":"1792_CR224","doi-asserted-by":"publisher","DOI":"10.1093\/bioadv\/vbae080","volume":"4","author":"F Lang","year":"2024","unstructured":"Lang F, Sorn P, Suchan M, Henrich A, Albrecht C, K\u00f6hl N, et al. Prediction of tumor-specific splicing from somatic mutations as a source of neoantigen candidates. Bioinforma Adv. 2024;4:vbae080.","journal-title":"Bioinforma Adv"},{"key":"1792_CR225","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01102-1","volume":"14","author":"E Fountzilas","year":"2022","unstructured":"Fountzilas E, Tsimberidou AM, Vo HH, Kurzrock R. Clinical trial design in the era of precision medicine. Genome Med. 2022;14:101.","journal-title":"Genome Med"},{"key":"1792_CR226","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.3389\/fonc.2020.01030","volume":"10","author":"G Nicora","year":"2020","unstructured":"Nicora G, Vitali F, Dagliati A, Geifman N, Bellazzi R. Integrated multi-omics analyses in oncology: a review of machine learning methods and tools. Front Oncol. 2020;10:1030.","journal-title":"Front Oncol"},{"key":"1792_CR227","doi-asserted-by":"publisher","DOI":"10.1126\/science.1254806","volume":"347","author":"HY Xiong","year":"2015","unstructured":"Xiong HY, Alipanahi B, Lee LJ, Bretschneider H, Merico D, Yuen RKC, et al. RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease. Science. 2015;347:1254806.","journal-title":"Science"},{"key":"1792_CR228","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Otal C, Lasarte-Cia A, Serrano D, Casares N, Conde E, Navarro F, et al. Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells. J Immunother Cancer. 2022;10:e004479.","DOI":"10.1136\/jitc-2021-004479"},{"key":"1792_CR229","first-page":"4535","volume":"24","author":"EJM Huijbers","year":"2010","unstructured":"Huijbers EJM, Ringvall M, Femel J, Kalamajski S, Lukinius A, Abrink M, et al. Vaccination against the extra domain-B of fibronectin as a novel tumor therapy. FASEB J Publ Fed Am Soc Exp Biol. 2010;24:4535\u201344.","journal-title":"FASEB J Publ Fed Am Soc Exp Biol"},{"key":"1792_CR230","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1145441","volume":"14","author":"L Tang","year":"2023","unstructured":"Tang L, Kong Y, Wang H, Zou P, Sun T, Liu Y, et al. Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia. Front Immunol. 2023;14:1145441.","journal-title":"Front Immunol"},{"key":"1792_CR231","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1043","volume":"12","author":"L Tang","year":"2022","unstructured":"Tang L, Huang H, Tang Y, Li Q, Wang J, Li D, et al. CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations. Clin Transl Med. 2022;12:e1043.","journal-title":"Clin Transl Med"},{"key":"1792_CR232","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.trecan.2024.01.003","volume":"10","author":"GJ Kembuan","year":"2024","unstructured":"Kembuan GJ, Kim JY, Maus MV, Jan M. Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology. Trends cancer. 2024;10:312\u201331.","journal-title":"Trends cancer"},{"key":"1792_CR233","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fimmu.2020.00176","volume":"11","author":"Z Wang","year":"2020","unstructured":"Wang Z, Cao YJ. Adoptive cell therapy targeting neoantigens: a frontier for cancer research. Front Immunol. 2020;11:176.","journal-title":"Front Immunol"},{"key":"1792_CR234","doi-asserted-by":"crossref","unstructured":"Biernacki MA, Lok J, Black RG, Foster KA, Cummings C, Woodward KB, et al. Discovery of U2AF1 neoantigens in myeloid neoplasms. J Immunother Cancer. 2023;11:e007490.","DOI":"10.1136\/jitc-2023-007490"},{"key":"1792_CR235","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1182\/blood.2021010858","volume":"138","author":"KP Micklethwaite","year":"2021","unstructured":"Micklethwaite KP, Gowrishankar K, Gloss BS, Li Z, Street JA, Moezzi L, et al. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood. 2021;138:1391\u2013405.","journal-title":"Blood"},{"key":"1792_CR236","doi-asserted-by":"crossref","unstructured":"Sagawa R, Sakata S, Gong B, Seto Y, Takemoto A, Takagi S, et al. Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation. JCI insight. 2022;7:e153323.","DOI":"10.1172\/jci.insight.153323"},{"key":"1792_CR237","doi-asserted-by":"publisher","first-page":"9114.","DOI":"10.1038\/s41467-024-53561-2","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, Liu T, Li Y, Ding A, Zhang C, Gu Y, et al. A splicing isoform of PD-1 promotes tumor progression as a potential immune checkpoint. Nat Commun. 2024;15:9114.","journal-title":"Nat Commun"},{"key":"1792_CR238","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.1038\/s44318-024-00262-7","volume":"43","author":"N Cho","year":"2024","unstructured":"Cho N, Kim S-Y, Lee S-G, Park C, Choi S, Kim E-M, et al. Alternative splicing of PBRM1 mediates resistance to PD-1 blockade therapy in renal cancer. EMBO J. 2024;43:5421\u201344.","journal-title":"EMBO J"},{"key":"1792_CR239","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1016\/j.molcel.2021.03.028","volume":"81","author":"T-Y Wang","year":"2021","unstructured":"Wang T-Y, Liu Q, Ren Y, Alam SK, Wang L, Zhu Z, et al. A pan-cancer transcriptome analysis of exitron splicing identifies novel cancer driver genes and neoepitopes. Mol Cell. 2021;81:2246\u20132260.e12.","journal-title":"Mol Cell"},{"key":"1792_CR240","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/cac2.12607","volume":"44","author":"J Cai","year":"2024","unstructured":"Cai J, Song L, Zhang F, Wu S, Zhu G, Zhang P, et al. Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy in hepatocellular carcinoma. Cancer Commun (Lond, Engl). 2024;44:1231\u201360.","journal-title":"Cancer Commun (Lond, Engl)"},{"key":"1792_CR241","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.763877","volume":"12","author":"RC Khanolkar","year":"2021","unstructured":"Khanolkar RC, Zhang C, Al-Fatyan F, Lawson L, Depasquale I, Meredith FM, et al. TGF\u03b22 Induces the Soluble Isoform of CTLA-4 - Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma. Front Immunol. 2021;12:763877.","journal-title":"Front Immunol"},{"key":"1792_CR242","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31055-3","volume":"13","author":"ZZ Gajic","year":"2022","unstructured":"Gajic ZZ, Deshpande A, Legut M, Imieli\u0144ski M, Sanjana NE. Recurrent somatic mutations as predictors of immunotherapy response. Nat Commun. 2022;13:3938.","journal-title":"Nat Commun"},{"key":"1792_CR243","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1080\/15476286.2019.1659080","volume":"16","author":"J Sun","year":"2019","unstructured":"Sun J, Bai J, Jiang T, Gao Y, Hua Y. Modulation of PDCD1 exon 3 splicing. RNA Biol. 2019;16:1794\u2013805.","journal-title":"RNA Biol"},{"key":"1792_CR244","doi-asserted-by":"crossref","unstructured":"Mahoney KM, Ross-Macdonald P, Yuan L, Song L, Veras E, Wind-Rotolo M, et al. Soluble PD-L1 as an early marker of progressive disease on nivolumab. J Immunother Cancer. 2022;10:e003527.","DOI":"10.1136\/jitc-2021-003527"},{"key":"1792_CR245","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ymthe.2023.11.028","volume":"32","author":"PT Kennedy","year":"2024","unstructured":"Kennedy PT, Saulters EL, Duckworth AD, Lim YJ, Woolley JF, Slupsky JR, et al. Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity. Mol Ther. 2024;32:457\u201368.","journal-title":"Mol Ther"},{"key":"1792_CR246","doi-asserted-by":"crossref","unstructured":"Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K, et al. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. J Clin Investig. 2024;134:e168318.","DOI":"10.1172\/JCI168318"},{"key":"1792_CR247","doi-asserted-by":"publisher","first-page":"8993","DOI":"10.1038\/s41598-024-59791-0","volume":"14","author":"SS Brun","year":"2024","unstructured":"Brun SS, Hansen TF, Wen SWC, Nyhus CH, Bertelsen L, Jakobsen A, et al. Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy. Sci Rep 2024;14:8993.","journal-title":"Sci Rep"},{"key":"1792_CR248","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1038\/s41467-025-57865-9","volume":"16","author":"JJ Orme","year":"2025","unstructured":"Orme JJ, Zhang H, Lingamaneni P, Kim Y, Lavoie R, Dorr M, et al. Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial. Nat Commun. 2025;16:2507.","journal-title":"Nat Commun"},{"key":"1792_CR249","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn6056","volume":"14","author":"S Matsushima","year":"2022","unstructured":"Matsushima S, Ajiro M, Iida K, Chamoto K, Honjo T, Hagiwara M. Chemical induction of splice-neoantigens attenuates tumor growth in a preclinical model of colorectal cancer. Sci Transl Med. 2022;14:eabn6056.","journal-title":"Sci Transl Med"},{"key":"1792_CR250","doi-asserted-by":"crossref","unstructured":"Ouyang P, Wang L, Wu J, Tian Y, Chen C, Li D, et al. Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors. Front Immunol. 2024;15:1344272.","DOI":"10.3389\/fimmu.2024.1344272"},{"key":"1792_CR251","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.cell.2020.12.031","volume":"184","author":"EA Bowling","year":"2021","unstructured":"Bowling EA, Wang JH, Gong F, Wu W, Neill NJ, Kim IS, et al. Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. Cell. 2021;184:384\u2013403.e21.","journal-title":"Cell"},{"key":"1792_CR252","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201899017","volume":"37","author":"Y Wu","year":"2018","unstructured":"Wu Y, Zhao W, Liu Y, Tan X, Li X, Zou Q, et al. Function of HNRNPC in breast cancer cells by controlling the dsRNA-induced interferon response. EMBO J. 2018;37:EMBJ201899017.","journal-title":"EMBO J"},{"key":"1792_CR253","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1042\/BST20230727","volume":"52","author":"AA Young","year":"2024","unstructured":"Young AA, Bohlin HE, Pierce JR, Cottrell KA. Suppression of double-stranded RNA sensing in cancer: molecular mechanisms and therapeutic potential. Biochem Soc Trans. 2024;52:2035\u201345.","journal-title":"Biochem Soc Trans"},{"key":"1792_CR254","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217432","volume":"611","author":"S Kong","year":"2025","unstructured":"Kong S, Zhang J, Wang L, Li W, Guo H, Weng Q, et al. Mechanisms of low MHC I expression and strategies for targeting MHC I with small molecules in cancer immunotherapy. Cancer Lett. 2025;611:217432.","journal-title":"Cancer Lett"},{"key":"1792_CR255","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","volume":"21","author":"I Heras-Murillo","year":"2024","unstructured":"Heras-Murillo I, Ad\u00e1n-Barrientos I, Gal\u00e1n M, Wculek SK, Sancho D. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat Rev Clin Oncol. 2024;21:257\u201377.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01792-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01792-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01792-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:16:25Z","timestamp":1782364585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01792-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":255,"alternative-id":["1792"],"URL":"https:\/\/doi.org\/10.1038\/s41418-026-01792-9","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}